Palladon (Hydromorphone Hydrochloride)

Hydromorphone hydrochloride is an opioid that acts on the central nervous system to relieve pain. It is used in several clinical situations where strong analgesia is required:

• Acute postoperative pain: provides rapid relief following surgery.
• Cancer‑related pain: helps control persistent pain associated with malignant disease.
• Severe chronic non‑cancer pain: used when other opioids are ineffective or not tolerated.
• Palliative care: contributes to comfort in end‑of‑life settings.

• Hydromorphone binds with high affinity to the mu‑opioid receptors in the central nervous system, inhibiting the release of excitatory neurotransmitters and reducing neuronal excitability. This receptor activation diminishes the perception of pain and alters the emotional response to painful stimuli, producing analgesia.

Hydromorphone may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects

• Nausea: occasional upset stomach and urge to vomit.
• Constipation: reduced bowel motility leading to hard stools.
• Drowsiness: feeling unusually sleepy or fatigued.
• Dizziness: light‑headed sensations, especially when standing.
• Dry mouth: reduced salivary flow causing a parched feeling.
• Sweating: increased perspiration without exertion.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing that can be fatal.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Cardiac arrhythmias: irregular heart rhythms that may require emergency care.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.
• Dependence and withdrawal: physical reliance developing with prolonged use.
• adrenal ​​​​​  ​  ​ ​ ​​ ​​ ​​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​​​

When prescribing hydromorphone, clinicians should consider several safety measures:

• Assess pain severity: confirm that opioid therapy is appropriate for the level of pain.
• Evaluate respiratory function: monitor for signs of respiratory depression, especially in opioid‑naïve patients.
• Review patient history: check for prior opioid use, substance‑use disorder, or hypersensitivity.
• Adjust for renal/hepatic impairment: dose may need modification in patients with organ dysfunction.
• Educate on constipation management: advise use of laxatives or stool softeners.
• Store at ambient temperature: keep below 25°C in the original packaging, protected from moisture.

Hydromorphone can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Benzodiazepines: combined use can markedly increase respiratory depression risk.
• CNS depressants: other sedatives or anesthetics may potentiate sedation and respiratory effects.
• MAO inhibitors: concurrent use can lead to unpredictable opioid reactions.

Moderate Interactions (Monitor Closely)

• Anticholinergics: may worsen constipation and urinary retention.
• CYP3A4 inhibitors: drugs such as ketoconazole can raise hydromorphone plasma levels.
• Diuretics: may enhance hypotensive effects, requiring blood pressure monitoring.